ClinicalTrials.gg
Active, not recruitingNCT06944509RADIQALUpdated Jun 12, 2026

RADIQAL Study (Radiation Dose and Image Quality Trial)

An interventional study of treatment with the Azurion system with Xres5 and Azurion with Clairy IQ in Coronary Artery Disease, sponsored by Philips Clinical & Medical Affairs Global. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Philips Clinical & Medical Affairs Global (part of Philips) · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
824
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Coronary Artery Disease by Philips — 1 open to participants now, 2 under way, none of them phase 3. Coronary Artery Disease · Philips.

Started
2025
the only one that year
No phase
6 of 13
1 open now
Registered
13th of 13
by date

Among the 13 studies in Coronary Artery Disease by Philips, this one is the only one that started in 2025, is one of 6 with no phase, and was the 13th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 13 studies in Coronary Artery Disease by Philips is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Coronary Artery Disease by Philips, or all of them as a file.
02

Study summary

The Azurion R4.0 is developed by Philips Medical Systems Nederland B.V., a Philips Healthcare company. The Azurion is an interventional X-ray system which is used for live X-ray imaging during invasive cardiac procedures. The proposed Azurion R4.0 includes new x-ray image postprocessing (Xres5) compared to its predecessor, which was equipped with ClarityIQ image post-processing (Xres4).

Azurion R4.0 is a cleared device for EU-MDR regulated countries, submission for FDA510K clearance in the US is pending. Sites in the US will only be activated in the study after FDA clearance.

This is a prospective, randomized, unblinded, comparative, international, multi-center clinical investigation. Randomization will be 1:1 between Xres5 and ClarityIQ (Xres4). Stratification will be performed per site on intended procedure type (based on clinical presentation) and patient BMI.

Primary objective is to demonstrate that in coronary procedures, Xres5 can reduce overall patient radiation dose compared to the current ClarityIQ without affecting procedural performance.

It is expected that 824 subjects are necessary to collect sufficient data for the evaluation of the objectives of this clinical study. The enrollment period is expected to last for 12 months. The study will be executed in Spain, Czech republic, Denmark and the US.

Read the detailed description

The study procedures consist of three main steps: 1) patient screening and written informed consent, 2) baseline assessment and randomization and 3) treatment with the Azurion system with Xres5 [intervention] or the standard of care (ClarityIQ/Xres4) [control]. Patients will be randomly assigned to either the intervention group or the control group (using the standard of care) in a 1:1 ratio. The coronary procedure will be conducted as per institutional standards and at the discretion of the operator, but the standard image processing will be based on the randomization result. If randomized to the intervention group (Xres5), it will always be possible for the operator to cross over to the standard of care imaging processing (Clarity IQ). For the study sites in EU the primary staff in the intervention room will be wearing electronic staff dosimeters which will log the radiation exposure per staff member per procedure.

After the procedure, characteristics of the patient and procedure are captured in an eCRF. The imaging runs will be uploaded in the cloud after de-identification. After the study the radiation dose (DAP and Air Kerma) will be read out from the system.

The study procedures will end after the coronary procedure is completed. There will be no modifications in the standard of care patient treatment or follow-up.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • invasive diagnostic procedures
  • diagnostic coronary angiographies
  • percutaneous coronary interventions
  • invasive coronary angiography
  • coronary artery disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject will be undergoing a diagnostic angiography and/or coronary intervention /elective PCI.
  • Subject is able to give written .
  • Subject is 18 years of age or older, or of legal age to give informed consent per state or national law.

Exclusion criteria

Exclusion Criteria:

  • Subject with known contrast allergy that cannot be adequately premedicated.
  • Subject with previous for diagnostic angiography and/or diagnostic/elective PCI.
  • Subject participates in a potentially confounding drug or device study during the course of the study.
  • All vulnerable subjects such as pregnant or breast-feeding women, or any other subject who meets an exclusion criteria according to applicable national laws, if any.
  • Subject unwilling or unable to comply with the protocol and/or unable to understand verbal and/or written .
  • Expected use of non-standard contrast concentrations (e.g. dilution of contrast).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
824 participants (estimated)

Study arms

  • Experimental
    Intervention (Xres5)

    treatment with the Azurion system with Xres5

    Device: treatment with the Azurion system with Xres5

  • Active comparator
    Control (ClarityIQ)

    the standard of care (ClarityIQ/Xres4)

    Other: Azurion with Clairy IQ

Interventions

  • Devicetreatment with the Azurion system with Xres5

    treatment with the Azurion system with Xres5

  • OtherAzurion with Clairy IQ

    Azurion system with the standard of care (ClarityIQ/Xres4)

06

What researchers measure

Primary outcomes

  1. Patient radiation dose and procedural performance (ClarityIQ vs Xres5)

    \- Cumulative Dose Area Product (DAP) \[Gycm2\] Total patient group - All procedure types

    Time frame: during study procedure

  2. Patient radiation dose and procedural performance (ClarityIQ vs Xres5)

    \- Cumulative Air Kerma (AK) \[Gy\] Total patient group - All procedure types

    Time frame: during study procedure

  3. Patient radiation dose and procedural performance (ClarityIQ vs Xres5)

    \- Time System in Use\* \[minutes\] Total patient group - All procedure types

    Time frame: during study procedure

Secondary outcomes

  1. Patient radiation dose and procedural performance - High BMI (ClarityIQ vs Xres5)

    \- Cumulative DAP \[Gycm2\] High BMI patients (BMI ≥ 30 kg/m2) - All procedures types

    Time frame: During study procedure

  2. Patient radiation dose and procedural performance - High BMI (ClarityIQ vs Xres5)

    \- Cumulative Air Kerma \[Gy\] High BMI patients (BMI ≥ 30 kg/m2) - All procedures types

    Time frame: During study procedure

  3. Patient radiation dose and procedural performance - High BMI (ClarityIQ vs Xres5)

    \- Time System in Use\* \[minutes\] High BMI patients (BMI ≥ 30 kg/m2) - All procedures types

    Time frame: During study procedure

  4. Patient radiation dose and procedural performance in diagnostic procedures (ClarityIQ vs Xres5)

    \- Cumulative DAP \[Gycm2\] Total patient group - ICA procedures

    Time frame: During study procedure

  5. Patient radiation dose and procedural performance in diagnostic procedures (ClarityIQ vs Xres5)

    \- Cumulative Air Kerma \[Gy\] Total patient group - ICA procedures

    Time frame: During study procedure

  6. Patient radiation dose and procedural performance in diagnostic procedures (ClarityIQ vs Xres5)

    \- Time System in Use\* \[minutes\] Total patient group - ICA procedures

    Time frame: During study procedure

  7. Patient radiation dose and procedural performance in interventional procedures (ClarityIQ vs Xres5)

    \- Cumulative DAP \[Gycm2\] Total patient group - PCI and ICA+PCI procedures

    Time frame: During study procedure

  8. Patient radiation dose and procedural performance in interventional procedures (ClarityIQ vs Xres5)

    \- Cumulative Air Kerma \[Gy\] Total patient group - PCI and ICA+PCI procedures

    Time frame: During study procedure

  9. Patient radiation dose and procedural performance in interventional procedures (ClarityIQ vs Xres5)

    \- Time System in Use\* \[minutes\] Total patient group - PCI and ICA+PCI procedures

    Time frame: During study procedure

  10. Coronary Cine Radiation Dose and procedural performance (ClarityIQ vs Xres5)

    \- Cumulative Cine Air Kerma \[Gy\] Total patient group - All procedure types - Coronary Cine Data

    Time frame: During study procedure

  11. Coronary Cine Radiation Dose and procedural performance (ClarityIQ vs Xres5)

    \- Cumulative Cine DAP \[Gycm2\] Total patient group - All procedure types - Coronary Cine Data

    Time frame: During study procedure

  12. Coronary Cine Radiation Dose and procedural performance (ClarityIQ vs Xres5)

    \- Time System in Use\* \[minutes\] Total patient group - All procedure types - Coronary Cine Data

    Time frame: During study procedure

  13. Coronary Cine Radiation Dose and procedural performance - High BMI (ClarityIQ vs Xres5)

    \- Cumulative Cine Air Kerma \[Gy\] High BMI patients (BMI ≥ 30 kg/m2) - All procedure types - Coronary Cine Data

    Time frame: During study procedure

  14. Coronary Cine Radiation Dose and procedural performance - High BMI (ClarityIQ vs Xres5)

    \- Cumulative Cine DAP \[Gycm2\] High BMI patients (BMI ≥ 30 kg/m2) - All procedure types - Coronary Cine Data

    Time frame: During study procedure

  15. Coronary Cine Radiation Dose and procedural performance - High BMI (ClarityIQ vs Xres5)

    \- Time System in Use\* \[minutes\] High BMI patients (BMI ≥ 30 kg/m2) - All procedure types - Coronary Cine Data

    Time frame: During study procedure

  16. Ultra-low dose cine fluoro rate (Xres5)

    \- Air Kerma rate per acquisitions \[mGy/minutes\] Xres5 cases - Total Patient group - All procedure types

    Time frame: During study procedure

Other outcomes

  1. Staff radiation dose (ClarityIQ vs Xres5)

    \- Deep dose Hp(10) \[mSv\] Total Patient group - All procedure types

    Time frame: During study procedure

  2. Staff radiation dose (ClarityIQ vs Xres5)

    \- Skin dose Hp(0.07) \[mSv\] Total Patient group - All procedure types

    Time frame: During study procedure

  3. Iodine contrast volume administered (ClarityIQ vs Xres5)

    \- Iodinated contrast volume \[ml\] Total Patient group - All procedure types

    Time frame: During study procedure

  4. Patient Radiation Dose - Projection Angles (ClarityIQ vs Xres5)

    \- DAP per run \[Gycm2\] Total Patient group - All procedure types

    Time frame: During study procedure

  5. Patient Radiation Dose - Projection Angles (ClarityIQ vs Xres5)

    \- Air Kerma per run \[Gy\] Total Patient group - All procedure types

    Time frame: During study procedure

07

Study locations

6 sites
08

References and documents

Publications

  • Philips Medical Systems Nederland B.V., "Safety and feasibility study with a new X-ray processing algorithm (Xres5) for coronary procedures"
  • Gislason-Lee AJ, Keeble C, Malkin CJ, Egleston D, Bexon J, Kengyelics SM, Blackman D, Davies AG. Impact of latest generation cardiac interventional X-ray equipment on patient image quality and radiation dose for trans-catheter aortic valve implantations. Br J Radiol. 2016 Nov;89(1067):20160269. doi: 10.1259/bjr.20160269. Epub 2016 Sep 29. PubMed 27610932 ↗
  • Nakamura S, Kobayashi T, Funatsu A, Okada T, Mauti M, Waizumi Y, Yamada S. Patient radiation dose reduction using an X-ray imaging noise reduction technology for cardiac angiography and intervention. Heart Vessels. 2016 May;31(5):655-63. doi: 10.1007/s00380-015-0667-z. Epub 2015 Apr 4. PubMed 25840815 ↗
  • Hruby A, Hu FB. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics. 2015 Jul;33(7):673-89. doi: 10.1007/s40273-014-0243-x. PubMed 25471927 ↗
  • Smith IR, Rivers JT. Measures of radiation exposure in cardiac imaging and the impact of case complexity. Heart Lung Circ. 2008 Jun;17(3):224-31. doi: 10.1016/j.hlc.2007.10.004. Epub 2008 Jan 31. PubMed 18242136 ↗
  • Cusma JT, Bell MR, Wondrow MA, Taubel JP, Holmes DR Jr. Real-time measurement of radiation exposure to patients during diagnostic coronary angiography and percutaneous interventional procedures. J Am Coll Cardiol. 1999 Feb;33(2):427-35. doi: 10.1016/s0735-1097(98)00591-9. PubMed 9973023 ↗
  • Fetterly KA, Lennon RJ, Bell MR, Holmes DR Jr, Rihal CS. Clinical determinants of radiation dose in percutaneous coronary interventional procedures: influence of patient size, procedure complexity, and performing physician. JACC Cardiovasc Interv. 2011 Mar;4(3):336-43. doi: 10.1016/j.jcin.2010.10.014. PubMed 21435613 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 22 months is close to that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 25, 2025
StartActual
May 14, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06944509
Responsible party
Sponsor
First posted
Apr 25, 2025
Start date
May 14, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jun 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion